Shenzhen Huada Gene will develop liquid biopsy tools in China using the technology of Clearbridge DioMedics in Singapore. The two have signed a cooperation agreement, the initial cooperation will focus on personalized medical applications in the field of lung cancer, breast cancer and liver cancer.
Clearbridge DioMedics, a biotech company that was spun off from the National University of Singapore, developed ClearCell FX1 to separate circulating tumor cells from blood samples.
According to the agreement, Huada Gene will develop further diagnostic clinical and research applications based on its own genetic technology. The two sides will conduct cancer and drug-related genetic analysis, single-cell analysis, and cancer immunotherapy research.
Johnson Chen, chairman and founder of Clearbridge DioMedics, believes that liquid biopsy plays a key role in clinical diagnosis and personalized medicine and may even help manage PD-L1 immunotherapy.
According to media reports, Huada Gene is considering listing in the A-shares at the end of this year. The management of the company has experienced changes in the past year and seems to indicate that the expansion plan will slow down.
Huada Gene was founded in 1999. Previously, the company also launched a series of cooperative transactions in the field of gene research big data service products.
Hard Capsule,Acne Remove Capsule,Skin Lighten Capsule,Anti-Inflammatory Capsule
Guangzhou Etechange Biological Engineering Co.,Ltd. , https://www.etechange.com